We are a clinical stage ophthalmic biopharmaceutical company developing a pipeline of Microdose Array Print (MAP™) therapeutics.
We aim to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using our high-precision targeted ocular delivery system, branded the Optejet®, which has the potential to replace conventional eyedropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than traditional eye drops (~ 90% vs. ~ 50%)1,2.
Our technology also can deliver up to a 75-80% reduction in ocular drug and preservative exposure3 and has demonstrated significant improvement in the therapeutic index in drugs used for mydriasis and IOP lowering through three Phase II and Phase III trials4,5. Using the Optejet, we are developing the next generation of smart ophthalmic therapeutics which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration, or the (FDA).
Our pipeline is currently focused on the late-stage development of microdosed medications for progressive myopia, presbyopia, and mydriasis.
1. Rathi, S and Scott, B. 2020, May. Evaluation of Topical Ophthalmic Medication Administration Using a Microdose Dispenser ( MiDD ) in Multiple Controlled Clinical Trials.
2. Naito, Tomoko et al. “Comparison of success rates in eye drop instillation between sitting position and supine position.” PloS one vol. 13,9 e0204363. 20 Sep. 2018, doi:10.1371/journal.pone.0204363.
3. American Academy of Ophthalmology (AAO). “Wouldn’t it be great if eyedrops didn’t spill out of your eyes?.” ScienceDaily. ScienceDaily, 13 November 2017.
4. Walters, Thomas. “Clinical Evaluation of a Micro-Dosed Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution for Dilation of the Pupil in Two Randomized, Controlled Phase 3 Trials (MIST-1 & MIST-2).” Eyenovia, Inc., 2019.
5. Pasquale LR, et al. Clin Ophthalmol . 2018;12:2451 2457.